Slide 1: FY26 results
For personal use only FY26 results 19 August 2026
Slide 2: Disclaimer
Disclaimer The information in this presentation was prepared by EBOS Group Limited (“EBOS” or the “Group”) with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and, to the extent permitted by law, no representation is made as to
Slide 3: Investment cycle complete; EBOS to continue its growth momentum
Investment cycle complete; EBOS to continue its growth momentum • FY26 revenue increased 9.9% and Underlying EBITDA increased 5.0% to $614 million, delivered within Solid growth; guidance1 investment cycle • Completed the four-year, $360 million DC renewal program, with all facilities now operationa
Slide 4: Delivered against all FY26 financial guidance metrics and Investor Day growth priorities
Delivered against all FY26 financial guidance metrics and Investor Day growth priorities Delivered on every financial guidance metric All FY26 guidance EBITDA Capex D&A Net finance costs Leverage For personal use only metrics delivered $614m $145m $148m $119m 2.1x within range1 Healthcare segment An
Slide 5: Underlying earnings remained resilient despite fuel and FX headwinds
Underlying earnings remained resilient despite fuel and FX headwinds Underlying growth drivers delivered $51m EBITDA uplift, partly offset by $22m of external cost headwinds For personal use only EBOS Group Underlying EBITDA breakdown (A$m) ✓ EBITDA growth of 5.0% reflects the underlying strength an
Slide 6: DC renewal program complete; network positioned to enable future growth & productivity
DC renewal program complete; Network now positioned to enable future growth & productivity Capex peaked in FY26 following completion of major DC …which has now positioned our assets to drive productivity renewal program…. and growth without further investment For personal use only Historical capex (
Slide 7: Repeatable bolt-on acquisitions expanded capability and market positions
Repeatable bolt-on acquisitions expanded capability and market positions In FY26 we deployed $121m capital across Premium chilled & fresh Scaled aesthetics and our M&A bolt-on program pet food capability reconstruction across SEA/HK For personal use only Retail Pharmacy • Australian manufacturer of
Slide 8: Healthcare results
For personal use only Healthcare results
Slide 9: Healthcare delivered resilient growth
Healthcare delivered resilient growth Medium to long-term industry trends have continued to shape our long-term financial performance Underlying EBITDA (A$m) For personal use only ex CWA ✓ Ageing and growing populations, driving sustained long-term demand for CWA medicines and healthcare services 80
Slide 10: Symbion & Healthcare Distribution: strong demand and network investment benefits emerging
Symbion & Healthcare Distribution: strong demand and network investment benefits emerging Community Pharmacy: Hospital medicines, Contract Logistics: Strong demand for GLP-1 and consumables & other: Customer wins and capacity high value medicines Resilient growth across all channels expansion drivin
Slide 11: Retail Pharmacy Brands: Customer loyalty and digital investments delivered strong earnings growth
Retail Pharmacy Brands: Customer loyalty and digital investments delivered strong earnings growth Key achievements and highlights in FY26 For personal use only • Total TWC network sales of $2.9bn, up 9.2% and like- TWC’s flu for-like sales up 7.6% and with total dispensary sales up vaccination share
Slide 12: Medical Technology: Expanded therapies, regional presence and biologics
Medical Technology: Expanded therapies, regional presence and biologics Key achievements and highlights in FY26 • FY26 revenue of $706m, increasing 5.5% (up 8.4% CCY1), reflecting solid contributions from organic led For personal use only growth and acquisitions, offset by FX headwinds and New ADM2
Slide 13: Animal Care results
13 For personal use only Animal Care results
Slide 14: Animal Care: Branded growth complemented by the addition of SVS
Animal Care: Branded growth complemented by the addition of SVS Animal Care has continued to outgrow the broader market, supported by structural tailwinds Underlying EBITDA (A$m) Acquired SVS For personal use only (wholesale margin Humanisation and premiumisation of pets, supporting demand for highe
Slide 15: Growth momentum underpinned by new product development and manufacturing capability
Growth momentum underpinned by new product development and manufacturing capability Hero Brands Innovative new offerings launched in last 12 months For personal use only High protein and highly palatable foods across base & complementary Paringa acquisition formats High Meat Wet Adult Dog Freeze Dri
Slide 16: Financial information
For personal use only Financial information
Slide 17: FY26 financial highlights
FY26 financial highlights1 Guidance Revenue EBITDA NPAT For personal use only delivered within range EBITDA2 $614m $13,487m $599m $225m Capex $145m D&A $148m 9.9% growth 7.8% growth 4.7% growth Net finance costs $119m Underlying EBITDA2 $614m Underlying NPAT $250m Leverage 2.1x (+5.0% growth) (3.1%
Slide 18: Key financials
Key financials A. Revenue increased 9.9%, driven by growth across Healthcare and Animal A$m FY26 FY25 Var% Care, including contribution from acquisitions Underlying results1 B. Underlying EBITDA increased 5.0%, demonstrating resilient earnings For personal use only Revenue 13,487 12,267 9.9% A growt
Slide 19: Disciplined capital allocation supporting cash generation and returns
Disciplined capital allocation supporting cash generation and returns For personal use only Maintained dividends whilst completing the investment cycle Allocation of capital in FY26 Shareholder Capex Operating Strong balance Operational Cash Growth returns2 cash flow sheet stability returns opportun
Slide 20: Strong liquidity with cash flow set to improve
Strong liquidity with cash flow set to improve • Leverage of 2.1x remains within the target range (1.7x to 2.3x), reflecting the peak of the Net debt (A$m) and Leverage ratio1 investment cycle 2.1x • Leverage expected to increase slightly in H1 FY27, due to the normal seasonal nature of cash For per
Slide 21: Disciplined working capital management; Capex peaked as investment cycle completed
Disciplined working capital management; Capex peaked as investment cycle completed Working capital (A$m) & cash conversion FY26 FY25 Var$ Net working capital well controlled; capex expected to moderate following Net working capital2 completion of the DC renewal program Trade & other receivables 1,66
Slide 22: Outlook
For personal use only Outlook
Slide 23: Execution of FY27 priorities supports mid single digit EBITDA growth
Execution of FY27 priorities supports mid single digit EBITDA growth, stronger cash generation and improving returns For personal use only Execution of divisional priorities… …translates into clear FY27 outcomes Symbion & Healthcare Distribution: “Put capacity to work” $635-655m EBITDA1 mid-single-d
Slide 24: Our proof points
Our proof points Strong positions with structural advantages The EBOS ~85% of our Group EBITDA is from EBOS has leading positions in essential care markets, leveraged to value story favourable structural tailwinds, underpinned by scale-driven businesses in #1 or #2 positions productivity and advanta
Slide 25: Appendix
For personal use only Appendix
Slide 26: Segment information
Segment information First Half Second Half Full Year Revenue GOR Revenue GOR Revenue GOR $m FY26 FY25 Var% FY26 FY25 Var% FY26 FY25 Var% FY26 FY25 Var% FY26 FY25 Var% FY26 FY25 Var% For personal use only Healthcare Community Pharmacy 3,610 3,144 14.8% 310 288 7.5% 3,503 3,312 5.8% 303 299 1.2% 7,113
Slide 27: Healthcare segment EBITDA by region
Healthcare segment EBITDA by region $m FY26 FY25 Change Healthcare segment For personal use only Revenue 12,580 11,593 8.5% Underlying EBITDA 516 500 3.2% Margin 4.1% 4.3% (20bps) Australia Revenue 9,679 8,958 8.0% Underlying EBITDA 424 397 6.7% Margin 4.4% 4.4% 0bps New Zealand & Southeast Asia Rev
Slide 28: Reconciliation of statutory to Underlying results
Reconciliation of statutory to Underlying results FY26 FY25 For personal use only $m Revenue EBITDA EBIT PBT NPAT Revenue EBITDA EBIT PBT NPAT Statutory result 13,487 599 419 299 225 12,267 556 409 302 215 M&A transaction costs - 5 5 5 4 - 11 11 11 10 Restructuring & site transition costs - 36 36 36
Slide 29: Segment EBITDA and EBIT reconciliation
Segment EBITDA and EBIT reconciliation EBITDA EBIT $m FY26 FY25 Var % FY26 FY25 Var% Healthcare Statutory 504 472 6.8% 344 339 1.3% Add M&A transaction costs 5 10 5 10 For personal use only Add Restructuring & site transition costs 33 18 33 18 Net gain on acquisition related activities (26) - (26) -
Slide 30: Glossary of terms and measures
Glossary of terms and measures Except where noted, common terms and measures used in this document are based upon the following definitions: Term Definition Revenue Revenue from the sale of goods and the rendering of services For personal use only Gross Operating Revenue (GOR) Revenue less cost of s
Slide 31: For personal use only
For personal use only